In a filing, BridgeBio Pharma Inc revealed its Director Frank McCormick acquired Company’s shares for reported $0.11 million on Oct 27 ’25. In the deal valued at $65.00 per share,1,641 shares were bought.
Then, Kumar Neil sold 40,000 shares, generating $2,192,092 in total proceeds. Upon selling the shares at $54.80, the Chief Executive Officer now owns 835,686 shares.
Before that, Kumar Neil sold 40,000 shares. BridgeBio Pharma Inc shares valued at $2,191,350 were divested by the Chief Executive Officer at a price of $54.78 per share. As a result of the transaction, Kumar Neil now holds 855,686 shares, worth roughly $54.39 million.
A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Jefferies began covering BBIO with “Buy” recommendation on July 14, 2025. Oppenheimer revised its rating on July 09, 2025. It rated BBIO as “an Outperform” which previously was an “a Perform”.
Price Performance Review of BBIO
On Monday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 17.14% to $63.56. Over the last five days, the stock has gained 12.99%. BridgeBio Pharma Inc shares have risen nearly 159.96% since the year began. Nevertheless, the stocks have risen 131.63% over the past one year. While a 52-week high of $57.49 was reached on 10/27/25, a 52-week low of $21.72 was recorded on 01/02/25.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 58.53, which if violated will result in even more drops to 53.51. On the upside, there is a resistance level at 66.79. A further resistance level may holdings at 70.03.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-10-15, dropping by -2.09 million shares to a total of 17.35 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 19.44 million shares. There was a decline of -12.04%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 17, 2025 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $49 price target.
